FindTrial
Sign In

Questionnaire survey on use of anti- allergic ophthalmic solutions for patients with seasonal allergic conjunctivitis in 2020

Questionnaire survey on use of anti- allergic ophthalmic solutions for patients with seasonal allergic conjunctivitis in 2020 - Questionnaire survey on use of anti- allergic ophthalmic solutions for patients with seasonal allergic conjunctivitis in 2020

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000039757
Enrollment
1000
Registered
2020-03-12
Start date
2020-03-12
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

seasonal allergic conjunctivitis

Interventions

None listed

Sponsors

Santen Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Subjects diagnosed with seasonal allergic conjunctivitis by ophthalmologist and used of anti- allergic ophthalmic solutions after the end of 2019. Subjects with seasonal allergic conjunctivitis such as eye itch after the end of 2019.

Exclusion criteria

Exclusion criteria: Medical professionals (doctors, pharmacists, nurses, etc.) Subjects engaged in pharmaceuticals and medical devices industry Subjects engaged in pharmaceuticals distributor Subjects engaged in information provision services, research services, and advertising Subjects with severe allergic conjunctival disease (vernal keratoconjunctivitis , atopic keratoconjunctivitis)

Design outcomes

Primary

MeasureTime frame
Relationship between drug adherence status and background of patients—

Countries

Japan

Contacts

Public ContactHirotsugu Kishimoto

Santen Pharmaceutical Co., Ltd. Japan Medical Affairs, Development Management Department, Japan Business

clinical@santen.co.jp06-4802-9603

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026